Drug Evaluation, Preclinical

"Drug Evaluation, Preclinical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.

Descriptor ID	D004353
MeSH Number(s)	E05.295.750 E05.337.550
Concept/Terms	Drug Evaluation, Preclinical Drug Evaluation, Preclinical Drug Evaluations, Preclinical Drug Screening Drug Screenings Screening, Drug Screenings, Drug Evaluation Studies, Drug, Pre-Clinical Preclinical Drug Evaluations Evaluation, Preclinical Drug Evaluations, Preclinical Drug Preclinical Drug Evaluation Drug Evaluation Studies, Preclinical Evaluation Studies, Drug, Preclinical Medicinal Plants Testing, Preclinical Medicinal Plants Testing, Preclinical

Below are MeSH descriptors whose meaning is more general than "Drug Evaluation, Preclinical".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Drug Discovery [E05.295]
Drug Evaluation, Preclinical [E05.295.750]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]

Below are MeSH descriptors whose meaning is related to "Drug Evaluation, Preclinical".

Below are MeSH descriptors whose meaning is more specific than "Drug Evaluation, Preclinical".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Evaluation, Preclinical" by people in this website by year, and whether "Drug Evaluation, Preclinical" was a major or minor topic of these publications.

Bar chart showing 99 publications over 24 distinct years, with a maximum of 9 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	3	3
1998	0	1	1
2000	0	1	1
2002	0	3	3
2003	0	1	1
2004	1	3	4
2005	1	2	3
2006	2	2	4
2007	0	2	2
2008	1	5	6
2009	2	4	6
2010	0	2	2
2011	0	6	6
2012	1	3	4
2013	1	7	8
2014	0	6	6
2015	1	8	9
2016	3	5	8
2017	1	5	6
2018	0	5	5
2019	0	2	2
2020	0	5	5
2021	0	3	3
2025	0	1	1

Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.

Pugsley MK, Bhatt S, Gottfridsson C, Hoffmann P, Koshman YE, Norton K, O'Brien CE, Pierson J, Rossman EI, Taraboletti A, Zabka TS, Foley CM. Advancing nonclinical blood pressure assessment: Current practices and future directions in drug development. Regul Toxicol Pharmacol. 2026 Aug; 169:106098.

View in: PubMed
Sarkar M, Du T, Chen Y, Lawrence YVM, Ma J, Khan SA, Oyelere AK, Liang D, Gao S, Xie H. Preclinical Development of GT-14, a Novel Inhibitor of Gai2 Protein: Comprehensive Evaluation of Physicochemical, Metabolic Characteristics and Tissue Distribution. AAPS J. 2025 12 01; 28(1):23.

View in: PubMed
Saeger S, West-Jeppson K, Liao Y-R, Campuzano A, Yu J-J, Lopez-Ribot J, Hung C-Y. Discovery of novel antifungal drugs via screening repurposing libraries against Coccidioides posadasii spherule initials. mBio. 2025 May 14; 16(5):e0020525.

View in: PubMed
Choudhary BS, Mehta P, Bach S, Ruchaud S, Robert T, Josselin B, Filipek S, Malik R. Discovery of thiazolidin-4-one analogue as selective GSK-3? inhibitor through structure based virtual screening. Bioorg Med Chem Lett. 2021 11 15; 52:128375.

View in: PubMed
Gonz?lez-Bl?zquez R, Alcal? M, Fern?ndez-Alfonso MS, Steckelings UM, Lorenzo MP, Viana M, Boisvert WA, Unger T, Gil-Ortega M, Somoza B. C21 preserves endothelial function in the thoracic aorta from DIO mice: role for AT2, Mas and B2 receptors. Clin Sci (Lond). 2021 05 14; 135(9):1145-1163.

View in: PubMed
Stojakovic A, Trushin S, Sheu A, Khalili L, Chang SY, Li X, Christensen T, Salisbury JL, Geroux RE, Gateno B, Flannery PJ, Dehankar M, Funk CC, Wilkins J, Stepanova A, O'Hagan T, Galkin A, Nesbitt J, Zhu X, Tripathi U, Macura S, Tchkonia T, Pirtskhalava T, Kirkland JL, Kudgus RA, Schoon RA, Reid JM, Yamazaki Y, Kanekiyo T, Zhang S, Nemutlu E, Dzeja P, Jaspersen A, Kwon YIC, Lee MK, Trushina E. Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice. Commun Biol. 2021 01 08; 4(1):61.

View in: PubMed
Brotherton-Pleiss C, Yue P, Zhu Y, Nakamura K, Chen W, Fu W, Kubota C, Chen J, Alonso-Valenteen F, Mikhael S, Medina-Kauwe L, Tius MA, Lopez-Tapia F, Turkson J. Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors. J Med Chem. 2021 01 14; 64(1):695-710.

View in: PubMed
Shao Y, Zhang QC. Targeting RNA structures in diseases with small molecules. Essays Biochem. 2020 12 07; 64(6):955-966.

View in: PubMed
Nichols TC, Levy H, Merricks EP, Raymer RA, Lee ML. Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. PLoS One. 2020; 15(10):e0240896.

View in: PubMed
Lorthiois E, Roache J, Barnes-Seeman D, Altmann E, Hassiepen U, Turner G, Duvadie R, Hornak V, Karki RG, Schiering N, Weihofen WA, Perruccio F, Calhoun A, Fazal T, Dedic D, Durand C, Dussauge S, Fettis K, Tritsch F, Dentel C, Druet A, Liu D, Kirman L, Lachal J, Namoto K, Bevan D, Mo R, Monnet G, Muller L, Zessis R, Huang X, Lindsley L, Currie T, Chiu YH, Fridrich C, Delgado P, Wang S, Hollis-Symynkywicz M, Berghausen J, Williams E, Liu H, Liang G, Kim H, Hoffmann P, Hein A, Ramage P, D'Arcy A, Harlfinger S, Renatus M, Ruedisser S, Feldman D, Elliott J, Sedrani R, Maibaum J, Adams CM. Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach. J Med Chem. 2020 08 13; 63(15):8088-8113.

View in: PubMed

People

Explore

Similar Concepts

Top Journals